The DOI matches its Crossref record.
Adenosine A2A or A3 receptors are required for inhibition of inflammation by methotrexate and its analog MX‐68
Open accessAbstract
Objective: Low‐dose weekly methotrexate therapy remains a mainstay in the treatment of inflammatory arthritis. Results of previous studies demonstrated that adenosine, acting at one or more of its receptors, mediates the antiinflammatory effects of methotrexate in animal models of both acute and chronic inflammation. We therefore sought to establish which receptor(s) is involved in the modulation of acute inflammation by methotrexate and its nonpolyglutamated analog MX‐68 (N‐[[4‐[(2,4‐diaminopteridin‐6‐yl)methyl]‐3,4‐dihydro‐2 H‐1,4‐benzothiazin‐7‐yl]‐carbonyl]‐L‐homoglutamic acid). Methods: We studied the effects of low‐dose methotrexate (0.75 mg/kg intraperitoneally [IP] every week for 5 weeks), MX‐68 (2 mg/kg IP 2 days and 1 hour before induction of inflammation), dexamethasone (1.5 mg/kg IP 1 hour before induction of inflammation), or vehicle control on acute inflammation in an air‐pouch model in A 2A and A 3 receptor knockout mice. Results: Low‐dose weekly methotrexate treatment increased the adenosine concentration in the exudates of all mice studied and reduced leukocyte and tumor necrosis factor α accumulation in the exudates of wild‐type mice, but not in those of A 2A or A 3 receptor knockout mice. Dexamethasone, an agent that suppresses inflammation by a different mechanism, was equally effective at suppressing leukocyte accumulation in A 2A knockout, A 3 knockout, and wild‐type mice, indicating that the lack of response was specific for methotrexate and MX‐68. Conclusion: These findings confirm that adenosine, acting at A 2A and A 3 receptors, is a potent regulator of inflammation. Moreover, these results provide strong evidence that adenosine, acting at either or both of these receptors, mediates the antiinflammatory effects of methotrexate and its analog MX‐68.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Adenosine Receptors as Therapeutic Targets
Jacobson, K. A., & Gao, Z.-G. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1983 · Cited by 1,431
Adenosine receptors: therapeutic aspects for inflammatory and immune diseases
Haskó, G., Linden, J., Cronstein, B., & Pacher, P. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2638 · Cited by 1,217
Self-citationAnti-Inflammatory Therapy in Chronic Disease: Challenges and Opportunities
Tabas, I., & Glass, C. K. (2013) · Science · doi:10.1126/science.1230720 · Cited by 1,093
Bours, M. J. L., Swennen, E. L. R., Di Virgilio, F., Cronstein, B. N., & Dagnelie, P. C. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.04.013 · Cited by 1,030
Self-citationAdenosine: an endogenous regulator of innate immunity
Haskó, G. (2004) · Trends in Immunology · doi:10.1016/j.it.2003.11.003 · Cited by 899
Inflammatory Resolution: new opportunities for drug discovery
Gilroy, D. W., Lawrence, T., Perretti, M., & Rossi, A. G. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1383 · Cited by 772
Methotrexate and its mechanisms of action in inflammatory arthritis
Cronstein, B. N., & Aune, T. M. (2020) · Nature Reviews Rheumatology · doi:10.1038/s41584-020-0373-9 · Cited by 677
Self-citationSide effects of methotrexate therapy for rheumatoid arthritis: A systematic review
Wang, W., Zhou, H., & Liu, L. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.09.027 · Cited by 562
Low-Dose Methotrexate: A Mainstay in the Treatment of Rheumatoid Arthritis
Cronstein, B. N. (2005) · Pharmacological Reviews · doi:10.1124/pr.57.2.3 · Cited by 535
Self-citationMethotrexate an Old Drug with New Tricks
Bedoui, Y., Guillot, X., Sélambarom, J., Guiraud, P., Giry, C., Jaffar-Bandjee, M. C., Ralandison, S., & Gasque, P. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20205023 · Cited by 471
Strategies toward rheumatoid arthritis therapy; the old and the new
Abbasi, M., Mousavi, M. J., Jamalzehi, S., Alimohammadi, R., Bezvan, M. H., Mohammadi, H., & Aslani, S. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.27860 · Cited by 443
Mechanisms of action of methotrexate
Genestier, L., Paillot, R., Quemeneur, L., Izeradjene, K., & Revillard, J.-P. (2000) · Immunopharmacology · doi:10.1016/s0162-3109(00)00189-2 · Cited by 424
Wessels, J. A. M., Huizinga, T. W. J., & Guchelaar, H.-J. (2007) · Rheumatology · doi:10.1093/rheumatology/kem279 · Cited by 337
Dervieux, T., Furst, D., Lein, D. O., Capps, R., Smith, K., Walsh, M., & Kremer, J. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20460 · Cited by 337
Koźmiński, P., Halik, P. K., Chesori, R., & Gniazdowska, E. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21103483 · Cited by 326
Immunomodulatory and neuroprotective effects of inosine
Haskó, G., Sitkovsky, M. V., & Szabó, C. (2004) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2004.01.006 · Cited by 308
Treatment of rheumatoid arthritis
Gaffo, A., Saag, K. G., & Curtis, J. R. (2006) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp050514 · Cited by 266
The ‘danger’ sensors that STOP the immune response: the A2 adenosine receptors?
Sitkovsky, M. V., & Ohta, A. (2005) · Trends in Immunology · doi:10.1016/j.it.2005.04.004 · Cited by 265
Bitto, A., Polito, F., Irrera, N., D'Ascola, A., Avenoso, A., Nastasi, G., Campo, G. M., Micali, A., Bagnato, G., Minutoli, L., et al. (2011) · Arthritis & Rheumatism · doi:10.1002/art.30538 · Cited by 105
Mediero, A., Perez‐Aso, M., & Cronstein, B. N. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12227 · Cited by 93
Self-citation
Metadata
- Authors
- Montesinos, M. C., Desai, A., Delano, D., Chen, J., Fink, J. S., Jacobson, M. A., & Cronstein, B. N.
- Venue
- Arthritis & Rheumatism
- Publisher
- Wiley
- Published
- 2003-01
- Volume
- 48
- Issue
- 1
- Pages
- 240-247
- ISSN
- 0004-3591 (ISSN-L)
- 1529-0131
- OpenAlex
- W1982767795
- Cited by
- 213
- References
- 0
- FWCI
- 7.91
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.